RecruitingNCT05759637
Type 2 Diabetes, Obesity and Cortisol Excess
Sponsor
Istituto Auxologico Italiano
Enrollment
3,200 participants
Start Date
May 6, 2022
Study Type
OBSERVATIONAL
Conditions
Summary
The present observational cross-sectional study is aimed to assess: the hidden hypercortisolism (HidHyCo) prevalence in a sample of Type 2 diabetes (T2D) patients and the clinical characteristics more frequently associated with the HidHyCo presence and the HidHyCo prevalence in an adequate sample of obese patients without T2D and the clinical characteristics more frequently associated with the HidHyCo presence.
Eligibility
Min Age: 18 YearsMax Age: 75 Years
Inclusion Criteria1
- patients with T2D and Obesity
Exclusion Criteria6
- pregnancy/breast feeding,
- sleep apnea,
- prepuberal onset of hypertension, hormonal hypersecreting adrenal mass,
- symptoms of hypercortisolism;
- already known secondary hypertension;
- conditions associated with increased hypothalamic-pituitary-adrenal (HPA) axis activity, -severe autoimmune/rheumatologic and hematologic diseases, alcoholism, kidney disease (glomerular filtration rate \<60)
Interventions
DIAGNOSTIC_TEST1mg DST
measurement of cortisol levels after 1 mg of dexamethasone (DST) at 11 pm
Locations(5)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05759637
Related Trials
A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK)
NCT0724708425 locations
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT070644731153 locations
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
NCT06112418115 locations
Testing an Integrated PTSD and Weight Management Intervention: A Hybrid Type 1 Trial
NCT070107571 location
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)
NCT074817471 location